Biotech & Health
ARPA-H Commits $117.4 Million to New Biosensor Projects
ARPA-H is committing up to $117.4 million to four biosensor projects targeting heart failure, inflammation and perimenopause.
2 articles
ARPA-H is committing up to $117.4 million to four biosensor projects targeting heart failure, inflammation and perimenopause.
Abbott’s CardioMEMS system gets FDA approval for new features that let patients view pressure readings and receive treatment updates on a smartphone.
Written by the reporters who cover each beat. Unsubscribe in one click.